Newsletter
3 Year Data Results Revealed for ReActiv8 Restorative Neurostimulation with Christopher Gilligan, Associate Chief Medical Officer at Brigham and Women’s Hospital

Outcomes Rocket

3 Year Data Results Revealed for ReActiv8 Restorative Neurostimulation with Christopher Gilligan, Associate Chief Medical Officer at Brigham and Women’s Hospital

October 3, 2022

3 Year Data Results Revealed for ReActiv8 Restorative Neurostimulation with Christopher Gilligan, Associate Chief Medical Officer at Brigham and Women’s Hospital

Exciting things are happening when it comes to back pain treatment!

In this episode, Dr. Chris Gilligan, Chief Medical Officer of the Division of Pain Medicine, Department of Anesthesiology, Perioperative, and Pain Medicine at Brigham and Women’s Hospital, speaks about new developments and therapies for the treatment of chronic low back pain. He explains how patients’ back pain is evaluated and categorized before treatment and the usual procedure based on that classification. He discusses different types of solutions, including a new restorative neurostimulation therapy that’s proving to have substantial clinical improvements. He’s found himself surprised at the outcomes it has brought for all different sorts of patients, including those with scoliosis and/or spondylolisthesis with zero lead migrations. Dr. Gilligan also talks about the long-term benefits for patients’ pain relief and economic savings.

Tune in to this episode to learn about what Dr. Chris Gilligan has to share on exciting new developments that will help many patients who suffer from chronic back pain!

Click this link to the show notes, transcript, and resources: outcomesrocket.health

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

Subscribe to Health Podcast Network

Join Our Newsletter

Proudly supported by:

cover
Adopting Clinical Trial Technology: The Key to Success for Patients, Sites, & Researchers Adoption of new clinical trial technologies is critical to success. These innovations can lift patient burden, improve patient engagement, and increase equity and access to clinical trials.